FDA: Gleevec's Latest Approval Is for Pediatric Cancer

Friday, January 25, 2013 (Last Updated: 01/28/2013)

FRIDAY, Jan. 25 (HealthDay News) -- The anti-cancer drug Gleevec (imatinib) has received new U.S. Food and Drug Administration approval to treat children newly diagnosed with Philadelphia chromosome positive (Ph+) acute lymphoblastic leukemia (ALL), the agency said Friday.

Ph+ ALL progresses rapidly if left untreated. Gleevec, among a class of drugs called tyrosine kinase inhibitors, blocks proteins that promote development of cancer cells, the FDA said in a news release.

The most common side effects observed in pediatric testing included infection and a decrease in white blood cells and blood platelets.

Gleevec was first approved in 2001 to treat a form of chronic myeloid leukemia, and has since been approved to treat several other conditions. The drug is marketed by Novartis, based in East Hanover, N.J.

More Information

Specialties Internal Medicine
Family Practice
Hematology & Oncology
Pathology
Pharmacy
OBGYN & Women's Health
Nursing

Copyright © 2013 HealthDay. All rights reserved.

Blogs

Living with more than one type of cancer
by Bob Riter
May 08, 2015

Breaking news: Supreme Court votes to uphold Affordable Care Act Subsidies
by Christina Bach, MSW, LCSW, OSW-C
June 26, 2015